2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Serologic Tests, Blood Banking, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Non-Biological Therapies, Opioids, Workforce, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Hemoglobinopathies, Sickle Cell Disease, Metabolic Disorders, Iron Overload, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4359 Assessing patient eligibility for CRISPR-Cas9 gene-editing therapy for pediatric sickle cell disease in a Canadian province: A cross-sectional database review

Madeleine Sumner, MD, Katherine Girgulis, MD2, Gurpreet Singh, MD3, Michael Leaker, MD4, Nicola Wright, MD5, Gregory Michael Taylor Guilcher, MD, FRCPC, DRCPSC, FAAP6
1 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
2 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
3 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
4 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
5 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada
6 University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada

Objectives: Exagamglogene autotemcel (Casgevy®), a CRISPR-Cas9 gene-editing therapy approved in Canada in January 2025, represents a transformative but resource-intensive curative option for severe sickle cell disease (SCD). Canada's Drug Agency (CDA) eligibility criteria require age ≥12 years, ≥2 severe vaso-occlusive crises (VOCs) per year for each of the past two years, normal transcranial Doppler (TCD), no 10/10 HLA-matched sibling donor, and no prior hematopoietic stem cell transplantation (HSCT) or excluding comorbidity. No real-world data exist on the proportion of patients meeting these criteria. We aimed to determine eligibility rates at a single Canadian pediatric centre, characterise reasons for ineligibility, and model the impact of proposed expansions. 

Methods: Cross-sectional chart review of all patients with severe-genotype SCD (HbSS, HbSβ°, HbSβ?) aged 4–17 years seen in the past 12 months at a tertiary pediatric hemoglobinopathy clinic, reviewed against each CDA criterion. Hydroxyurea compliance and fetal hemoglobin (HbF) were recorded for all eligible patients. Secondary analyses modelled eligibility under: a) lower age threshold (≥4 years); b) inclusion of patients on chronic transfusion therapy (CTT) for VOC control; c) inclusion of patients with elevated TCD; and d) a relaxed VOC threshold of ≥4 total events over two years. Data are reported as frequencies and percentages. 

Results: Of 213 patients screened, 134 (62.9%) underwent full chart review (mean age 10.5 ± 3.9 years; 51.5% male; 96.3% HbSS, 2.2% HbSβ?, 1.5% HbSβ°). Only 7 patients (5.2% of reviewed; 3.3% of total screened) met all CDA criteria. All 7 had documented hydroxyurea compliance concerns and 6/7 had HbF <20%, suggesting suboptimal standard-of-care adherence as a contributor to the severe phenotype required for eligibility. The dominant barrier was insufficient VOC frequency (n=119; 96.7% of ineligible patients), followed by HLA-matched sibling donor availability (n=29; 23.5%), prior HSCT (n=10; 8.1%), abnormal TCD (n=7; 5.7%), and stroke history (n=5; 4.1%). Of 124 patients without prior HSCT, 45 (36.3%) had no VOCs in either 2024 or 2025. Under expanded criteria, lowering the age threshold to ≥4 years would add 4 patients (11 total; 5.2% of total). Inclusion of patients on CTT for VOC control yielded no additional eligible patients, as both patients on CTT for this indication had an HLA-matched sibling or had undergone HSCT. Inclusion of those with elevated TCD also yielded no additional patients, as all failed the VOC frequency requirement. Applying the relaxed VOC threshold increased the cohort to 13 patients (9.7%). Under no expansion scenario did eligible patients exceed 10% of the reviewed cohort. 

Conclusions: Fewer than 1 in 20 pediatric SCD patients at our pediatric institution meet current Canada's Drug Agency eligibility criteria for Casgevy®, with VOC frequency the dominant barrier across all modelled scenarios. The finding that all eligible patients had hydroxyurea compliance concerns raises important questions about the role of treatment adherence in determining eligibility and warrants further study. These first real-world Canadian eligibility estimates suggest initial demand will be modest but will likely grow as age criteria expand and clinical experience accumulates. Our data provides a critical empirical foundation for resource planning and real-life application of reimbursement criteria, both in Canada and in other countries around the world as this new therapy becomes more readily available on a global scale.  

 

Madeleine Sumner, MD: No relevant conflicts of interest to declare.